General
Preferred name
PALOVAROTENE
Synonyms
Ro 3300074 ()
R 667 ()
RG-667 ()
RO3300074 ()
IPN60120 ()
Sohonos ()
IPN-60120 ()
RO-3300074 ()
R-667 ()
CLM-001 ()
P&D ID
PD051251
CAS
410528-02-8
Tags
available
drug
Approved by
FDA
First approval
2023
Drug Status
investigational
approved
Drug indication
Fibrodysplasia ossificans progressiva
Emphysema
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Palovarotene is an orally bioavailable, retinoic acid receptor gamma (RAR-γ) agonist. This compound was originally investegated for its potential to repair alveolar damage in emphysema and COPD , but it failed to demonstrate significant clinical efficacy. Ipsen acquired palovarotene when it purchased Clementia Pharmaceuticals in 2019, and they repurposed palovarotene for potential to reduce heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP) . (GtoPdb)
Compound Sets
13
AdooQ Bioactive Compound Library
A12430
Cayman Chemical Bioactives
28460
ChEMBL Drugs
CHEMBL2105648
Drug Repurposing Hub
DrugBank
DB05467
DrugBank Approved Drugs
DB05467
DrugCentral
5737
DrugCentral Approved Drugs
5737
DrugMAP
DMAD2OZ
Guide to Pharmacology
8276
MedChem Express Bioactive Compound Library
HY-14799
ReFrame library
TargetMol Bioactive Compound Library
T4538
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
414.23
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
6.15
TPSA
55.12
Fraction CSP3
0.33
Chiral centers
0.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Autophagy
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Target
RAR??
RAR¦Ã
RARG
RAR/RXR
MOA
Retinoid Receptor agonist
Source data